{"id":249784,"date":"2023-10-03T00:00:00","date_gmt":"2023-10-03T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcg0122-biopharma-myasthenia-gravis-epidemiology-mature-markets\/"},"modified":"2026-03-31T10:32:07","modified_gmt":"2026-03-31T10:32:07","slug":"epidcg0122-biopharma-myasthenia-gravis-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcg0122-biopharma-myasthenia-gravis-epidemiology-mature-markets\/","title":{"rendered":"Myasthenia Gravis &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of myasthenia gravis (<abbr title=\"myasthenia gravis\">MG<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of <abbr title=\"myasthenia gravis\">MG<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"myasthenia gravis\">MG<\/abbr> forecast will answer the following question:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"myasthenia gravis\">MG<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS <\/span>Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts five <abbr title=\"myasthenia gravis\">MG<\/abbr> patient populations in the major mature pharmaceutical markets, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed prevalent cases of <abbr title=\"myasthenia gravis\">MG<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of ocular <abbr title=\"myasthenia gravis\">MG<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of generalized <abbr title=\"myasthenia gravis\">MG<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of anti-<span class=\"abbreviation-guard\">AChR<\/span>-seropositive <abbr title=\"myasthenia gravis\">MG<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of thymoma <abbr title=\"myasthenia gravis\">MG<\/abbr>.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-249784","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-neurology","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249784\/revisions"}],"predecessor-version":[{"id":281349,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249784\/revisions\/281349"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}